Abiopharma

🔍 Claypoole Robert E (Director)

Company: Bioventus Inc. (BVS)

Report Date: 2026-01-09

Detailed Transactions and Holdings:

• Acquired 93,750 shares of Class A Common Stock (Direct)
  Date: 2026-01-09 | Code: M | equity_swap_involved: 0 | shares_owned_after: 158,714.00 | transaction_form_type: 4
• Sold 41,717 shares of Class A Common Stock at $8.03 per share (Direct)
  Date: 2026-01-09 | Code: F | equity_swap_involved: 0 | shares_owned_after: 116,997.00 | transaction_form_type: 4
• Sold 93,750 shares of Restricted Stock Units (Derivative)
  Date: 2026-01-09 | Code: M | equity_swap_involved: 0 | shares_owned_after: 187,500.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2

Footnotes:

• F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.
• F2: The RSUs shall vest in four equal installments on each of the first four anniversaries of January 10, 2024, in each case subject to the Reporting Person continuing in service through the applicable vesting date.